The National Academy of Sciences hosted a two-day event to highlight ADHD adults in December 2023. Here are some of the highlights.
Margaret Sibley, Ph.D., discussed the lack of equitable NIH (National Institute of Health) funding for adult ADHD research. Despite affecting a more significant total number of adults than children, the NIH is estimated to spend $78 million on ADHD research in children compared to only $5.5 million for ADHD research in adults. This amount spent on ADHD research is less than 13% of the $650 million spent by the NIH on depression research.
Ann C. Childress, MD, president of APSARD, reported that adult ADHD is one of the most common mental health conditions in the United States, with a prevalence of 4.4% in adults. She said untreated ADHD becomes progressively more fatal as comorbid conditions, such as depression, anxiety, insomnia, and substance abuse, begin stacking on top of the progressively devastating consequences of untreated ADHD. The mortality rate for ADHD is 150% of the general population. ADHD with one associated comorbid condition is 450% of the general population, and with two comorbidities, it is staggeringly 850% that of the general population.
Amy Arnsten, Ph.D., discussed a small study that showed that, despite the widespread usage of stimulants, only 23% of patients stated that they were fully satisfied with their current stimulant treatment. In addition, adults are more frequently prescribed short-acting stimulants, while children are usually prescribed long-acting versions.